Musculoskeletal (MSK) Infection Clinical Practice Guideline

Emergency Department Management

Page 1 of 4 Final 11/2/18 Updated 8/2023



Developed through the efforts of Children's Healthcare of Atlanta and physicians on Children's medical staff in the interest of advancing pediatric healthcare. This is a general guideline and does not represent a professional care standard governing providers' obligation to patients. Ultimately the patient's physician must determine the most appropriate care. © 2018 Children's Healthcare of Atlanta, Inc.

Musculoskeletal (MSK) Infection Clinical Practice Guideline

Inpatient Management

Page 2 of 4 Final 11/2/18 Updated 8/2023



Developed through the efforts of Children's Healthcare of Atlanta and physicians on Children's medical staff in the interest of advancing pediatric healthcare. This is a general guideline and does not represent a professional care standard governing providers' obligation to patients. Ultimately the patient's physician must determine the most appropriate care. © 2018 Children's Healthcare of Atlanta, Inc.



IV Antibiotic Table					
Patient Characteristics	Bacterial Targets	Drug	Dose	Max Single Dose	
6 months - ≤ 4 years and	S. aureus , S. pyogenes (GAS),	Clindamycin AND	13mg/kg IV q8h	900mg	
edically stable	K. kingae	Cefazolin	40mg/kg IV q8h	2000mg	
6 months - ≤ 4 years	S. aureus , S. pyogenes (GAS),	Clindamycin AND	13mg/kg IV q8h	900mg	
and not fully immunized against H. influenzae or S. pneumoniae	K. kingae , H. influenzae , S. pneumoniae	Ceftriaxone	75mg/kg IV q24h	2000mg	
> 6 months and ill appearing (Hemodynamically instability OR anticipated/existing need for intensive care)	S. aureus , S. pyogenes (GAS), K. kingae , H. influenzae , S. pneumoniae	Vancomycin ¹ AND	15mg/kg IV q6h	1000 mg	
		Ceftriaxone	75mg/kg IV q24h	2000mg	
		<i>Consider</i> Clindamycin ²	13mg/kg IV q8h	900mg	
> 4 years old and medically stable	S. aureus , S. pyogenes (GAS)	Clindamycin	13mg/kg IV q8h	900mg	
		<i>Consider</i> Ceftriaxone ³	75mg/kg IV q24h	2000mg	
¹ Recommended vancomycin st ² Consider adding clindamycin em	trough levels and a	adjust accordingly.			

Consider adding clindamycin empirically in critically ill patients while waiting for confirmation of therapeutic vancomycin level.

³ If not fully immunized against *H. influenzae* or *S. pneumoniae* OR concern for Lyme disease or Gonorrhea, add ceftriaxone.

Suggested Antibiotics for PO Transition				
Bacterial Targets	Drug	Dose	Max Single Dose	
MSSA or K. kingae	Cephalexin	40mg/kg/dose q8h	1000mg	
MRSA	Clindamycin	13mg/kg/dose q8h	600mg	
S. pyogenes (GAS)	Amoxicillin	30mg/kg/dose q8h	1000mg	



Developed through the efforts of Children's Healthcare of Atlanta and physicians on Children's medical staff in the interest of advancing pediatric healthcare. This is a general guideline and does not represent a professional care standard governing providers' obligation to patients. Ultimately the patient's physician must determine the most appropriate care. © 2018 Children's Healthcare of Atlanta, Inc.